CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

Trial Profile

CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Linagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms CARMELINA
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 15 Sep 2017 Baseline characteristics of the treated study population (n=6978) randomized between July 2013 and August 2016, were presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
    • 13 Jun 2017 Results (n=6978 randomized between July 2013 and August 2016) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 07 Jun 2017 Planned End Date changed from 1 Jan 2018 to 11 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top